Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cells
c. yang, C. Tian, T. E. Hoffman, N. K. Jacobsen, S. L. Spencer
Abstract
Despite increasing numbers of effective anti-cancer therapies, successful treatment is limited by the development of drug resistance. While the contribution of genetic factors to drug resistance is undeniable, little is known about how drug-sensitive cells first evade drug action to proliferate in drug. Here we track the response of thousands of single melanoma cells to BRAF inhibitors and show that a subset escapes drug within the first 3 days of treatment. Cell-cycle re-entry occurs via a non-genetic mechanism involving activation of mTORC1 and ATF4, validated in cultures of patient biopsies. These escapees cycle periodically in drug, incur significant DNA damage, and out-proliferate non-escapees over extended treatment. Our work reveals a mutagenesis-prone, expanding subpopulation of early drug escapees that may seed development of permanent drug resistance.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Sporadic ERK pulses drive non-genetic resistance in drug-adapted BRAFV600E melanoma cells
L. Gerosa, C. Chidley, … P. K. Sorger·bioRxiv·Sep 8, 2019
- Multiple cancer types rapidly escape from multiple MAPK inhibitors to generate mutagenesis-prone subpopulations
T. E. Hoffman, C. Yang, … S. L. Spencer·bioRxiv·Mar 17, 2023
- BRAF inhibitor resistance confers increased sensitivity to mitotic inhibitors
S. Misek, T. Dexheimer, … K. A. Gallo·bioRxiv·Apr 15, 2021
- Growth rate-driven modelling suggests that phenotypic adaptation drives drug resistance in BRAFV600E-mutant melanoma
Sara Hamis, Alexander P. Browning, … Tyler Cassidy·Communications BiologyPeer-reviewed·Feb 26, 2026
- Trajectories from Snapshots: Integrated proteomic and metabolic single-cell assays reveal multiple independent adaptive responses to drug tolerance in a BRAF-mutant melanoma cell line
Y. Su, G. Li, … J. R. Heath·bioRxiv·Sep 12, 2019
- Computational Model of Heterogeneity in Melanoma: Designing Therapies and Predicting Outcomes
Arran Hodgkinson, Dumitru Trucu, … Ovidiu Radulescu·Frontiers in OncologyPeer-reviewed·Apr 14, 2022